Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | July 07, 2025 | July 10, 2025 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Chief Executive Officer | February 07, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date July 07, 2025 · Filed July 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,846 |
Reported balance
After 2025-07-07 transaction · row 1
1 source rowRow 1 · 2025-07-07 · Sale · Disposed 10,000 · Balance 308,846 F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,220 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 58,220 |
| Common StockSEC Table I · non-derivative | IndirectBy The Maag Family Irrevocable Trust | 349,321 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 349,321 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-07-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2032-11-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,368 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 62,092 · Balance 58,368 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 58,368 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2022 Filed Mar 8, 2022 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,373 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001217234-22-000062 · wf-form4_164677775584433.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,294 Underlying: Common Stock · 2,373 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,683 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001217234-22-000062 · wf-form4_164677775584433.xml · derivative · entry 7 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,067 Underlying: Common Stock · 1,683 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,500 | $33.75 | $50,626.80 |
DisclosureSEC source: 0001217234-22-000062 · wf-form4_164677775584433.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,739 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.31 to $34.26, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 8,500 | $32.64 | $277,435.75 |
DisclosureSEC source: 0001217234-22-000062 · wf-form4_164677775584433.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,239 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.285 to $33.26, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 2,373 | $24.35 | $57,782.55 |
DisclosureSEC source: 0001217234-22-000062 · wf-form4_164677775584433.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 1,683 | $12.24 | $20,599.92 |
DisclosureSEC source: 0001217234-22-000062 · wf-form4_164677775584433.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 02:58 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 5,100 | $42.32 | $215,847.30 |
DisclosureSEC source: 0001217234-22-000042 · wf-form4_164437547646887.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,683 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.095 to $42.635, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 02:58 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 4,900 | $41.80 | $204,820.98 |
DisclosureSEC source: 0001217234-22-000042 · wf-form4_164437547646887.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,783 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.085 to $42.080, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 22:46 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 1,132 | $40.08 | $45,370.56 |
DisclosureSEC source: 0001217234-22-000036 · wf-form4_164401474105150.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,683 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| January 29, 2022 Filed Feb 4, 2022 01:23 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 3,417 | $38.51 | $131,588.67 |
DisclosureSEC source: 0001217234-22-000027 · wf-form4_164393781432611.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,815 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| January 19, 2022 Filed Feb 4, 2022 01:23 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 3,822 | $37.46 | $143,172.12 |
DisclosureSEC source: 0001217234-22-000027 · wf-form4_164393781432611.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,232 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,735 | $0.00 Strike: $27.17 | $0.00 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · derivative · entry 10 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,164 Underlying: Common Stock · 5,735 shares Expires 2029-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 25, 2020 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,340 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 3,340 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 925 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 925 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vested January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,854 | $45.13 | $83,676.77 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,756 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45 to $45.29, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 8,146 | $44.29 | $360,788.78 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,610 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.85 to $44.80, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,735 | $27.17 | $155,819.95 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,340 | $24.35 | $81,329.00 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 23:07 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 925 | $6.31 | $5,836.75 |
DisclosureSEC source: 0001217234-22-000012 · wf-form4_164151044216434.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,949 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · derivative · entry 11 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,007 Underlying: Common Stock · 5,949 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · derivative · entry 10 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,125 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 926 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,090 Underlying: Common Stock · 926 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 300 | $42.61 | $12,782.01 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · nonDerivative · entry 6 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,756 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $42.625, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,112 | $42.20 | $131,337.29 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,056 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.57 to $42.55, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 6,588 | $41.30 | $272,070.57 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,168 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.56 to $41.54, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,949 | $24.35 | $144,858.15 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,125 | $12.24 | $38,250.00 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 926 | $6.31 | $5,843.06 |
DisclosureSEC source: 0001217234-21-000253 · wf-form4_163891253544976.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,950 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,956 Underlying: Common Stock · 5,950 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 3,125 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 925 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · derivative · entry 7 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 Underlying: Common Stock · 925 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,000 | $49.40 | $494,000.00 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,756 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,950 | $24.35 | $144,882.50 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,125 | $12.24 | $38,250.00 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 23:01 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 925 | $6.31 | $5,836.75 |
DisclosureSEC source: 0001217234-21-000242 · wf-form4_163649883978199.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,347 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · derivative · entry 11 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,906 Underlying: Common Stock · 5,347 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,727 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · derivative · entry 10 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 3,727 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 926 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,941 Underlying: Common Stock · 926 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 1,163 | $65.90 | $76,644.72 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · nonDerivative · entry 6 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,756 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.59 to $66.25, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,612 | $64.95 | $234,587.48 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,919 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.55 to $65.53, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 5,225 | $64.21 | $335,502.48 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,531 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.52 to $64.52, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,347 | $24.35 | $130,199.45 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,727 | $12.24 | $45,618.48 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 23:40 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 926 | $6.31 | $5,843.06 |
DisclosureSEC source: 0001217234-21-000225 · wf-form4_163356364178749.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 00:36 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,523 | $12.24 Strike: $12.24 | $30,881.52 |
DisclosureSEC source: 0001217234-21-000210 · wf-form4_163106136222067.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,727 Underlying: Common Stock · 2,523 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 00:36 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 925 | $6.31 Strike: $6.31 | $5,836.75 |
DisclosureSEC source: 0001217234-21-000210 · wf-form4_163106136222067.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,867 Underlying: Common Stock · 925 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 00:36 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 300 | $75.31 | $22,593.99 |
DisclosureSEC source: 0001217234-21-000210 · wf-form4_163106136222067.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,756 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.25 to $75.38, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 00:36 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 900 | $74.32 | $66,888.99 |
DisclosureSEC source: 0001217234-21-000210 · wf-form4_163106136222067.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,056 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.13 to $74.43, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 00:36 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 8,800 | $73.55 | $647,279.60 |
DisclosureSEC source: 0001217234-21-000210 · wf-form4_163106136222067.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,956 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.10 to $74.055, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 00:36 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 2,523 | $12.24 | $30,881.52 |
DisclosureSEC source: 0001217234-21-000210 · wf-form4_163106136222067.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.